RRC ID 43566
著者 Li CF, Fang FM, Wang JM, Tzeng CC, Tai HC, Wei YC, Li SH, Lee YT, Wang YH, Yu SC, Shiue YL, Chu PY, Wang WL, Chen LT, Huang HY.
タイトル EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.
ジャーナル Ann Surg Oncol
Abstract BACKGROUND:The understanding of epidermal growth factor receptor (EGFR) deregulation in carcinogenesis remains incomplete. We investigated the implications of EGFR gene status and EGFR nuclear translocation in gallbladder carcinoma (GBCA).
METHODS:Subcellular localization of EGFR and phosphorylated EGFR (pEGFR) was analyzed by fractional immunoblotting and confocal immunofluorescence in GBCA cell lines. pEGFR binding to iNOS promoter was assessed by chromatin immunoprecipitation with iNOS promoter activity evaluated by luciferase assay. EGFR, pEGFR, and iNOS were immunohistochemically assessable for localization and level in the training set of 104 GBCAs on tissue microarrays, with 76 cases analyzed for EGFR gene by chromogenic in situ hybridization (CISH) and mutant-enriched PCR targeting exons 19 and 21. The prognostic impact of nuclear pEGFR (N-pEGFR) immunoexpression was reaffirmed on whole sections of 58 GBCAs in the test set.
RESULTS:Nuclear expression of EGFR and pEGFR was substantiated in vitro with augmented activity of iNOS promoter elicited by pEGFR binding upon EGF treatment. Despite no mutation, EGFR amplification, identified in 11 cases (15%) by CISH, strongly correlated with cytoplasmic EGFR expression (P < 0.001) but not with disease-specific survival (DSS). Immunoexpression of nuclear EGFR (N-EGFR), cytoplasmic pEGFR, and N-pEGFR was strongly related to that of iNOS (all ≤0.005). N-pEGFR independently predicted worse DSS in both training (P = 0.0468, HR = 2.024) and test sets (P = 0.0223, HR = 5.573).
CONCLUSIONS:N-EGFR and N-pEGFR express in GBCA, conferring clinical aggressiveness partly through iNOS transactivation. Lacking response-predicting mutation, EGFR gene status, albeit amplified in 15% of GBCA, is neither related to nuclear EGFR translocation nor prognostically useful.
巻・号 19(2)
ページ 443-54
公開日 2012-2-1
DOI 10.1245/s10434-011-1942-6
PMID 21761100
MeSH Active Transport, Cell Nucleus Adenocarcinoma / genetics Adenocarcinoma / metabolism* Adenocarcinoma / mortality Aged Blotting, Western Carcinoma, Papillary / genetics Carcinoma, Papillary / metabolism* Carcinoma, Papillary / mortality Cell Nucleus / metabolism* Chromatin Immunoprecipitation Cytoplasm / metabolism ErbB Receptors / genetics ErbB Receptors / metabolism* Female Fluorescent Antibody Technique Gallbladder Neoplasms / genetics Gallbladder Neoplasms / metabolism* Gallbladder Neoplasms / mortality Gene Expression Regulation, Neoplastic* Humans Immunoenzyme Techniques In Situ Hybridization Luciferases / metabolism Male Mutation / genetics Nitric Oxide Synthase Type II / genetics* Nitric Oxide Synthase Type II / metabolism Phosphorylation Prognosis Promoter Regions, Genetic RNA, Messenger / genetics Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction Signal Transduction Survival Rate Tumor Cells, Cultured Up-Regulation
IF 4.061
引用数 15
WOS 分野 SURGERY ONCOLOGY
リソース情報
ヒト・動物細胞